Unilife Corporation (UNS)

Shares / Stock Code

UNS

Stock Exchange / Sharemarket

ax

Unilife (UNS) is a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for their products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. All of their syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. UNS is ISO 13485 certified and have FDA-registered medical device manufacturing facilities in Pennsylvania. was listed on the Australian stock market in 18 January, 2010.

UNS is the successor entity to Unilife Medical Solutions Limited. The Company develops and supplies innovative safety medical devices. Investors can trade Unilife shares on the Australian Stock Exchange (ASX).

The company's main product is the Unifilltm ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. They have a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill syringe and is funding their industrialization program. In addition, they have retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.

Unilife has built a significant relationship with sanofi-aventis for the development and industrialization of the Unifill ready-to-fill syringe. Sanofi-aventis is one of the world leaders in the pharmaceutical market, and the largest global consumers of prefilled syringes.

Under an exclusive agreement entered into by both parties on July 1, 2008, sanofi-aventis paid to Unilife A$16.4 million (€10 million) for the exclusive right to negotiate for the purchase of the Unifill syringe and to bear the costs of its industrialisation subject to the signing of the Industrialisation Agreement and the completion of agreed quarterly milestones. Unilife subsequently entered into an Industrialisation Agreement with sanofi-aventis for the commercialization of Unifill syringe in July 2009. These Agreements set forth the terms of the on-going relationship of the parties, including sanofi-aventis’ commitment to complete the funding of the A$30.4 million (€17 million) Unifill syringe industrialisation program that Unilife commenced in July 2008 subject to the ongoing completion of project milestones. Furthermore, the Agreements outline the agreed pricing structure under which sanofi-aventis will purchase the Unifill syringe, subject to the signing of a Supply Agreement, and provide to Unilife the right to supply the Unifill syringe to other pharmaceutical companies in certain therapeutic drug classes to negotiated between the parties.